Skip to main content

Table 1 Baseline characteristics by allocation group (intention-to-treat analysis set)

From: Bronchiectasis Information and Education: a randomised, controlled feasibility trial

  Control group
(n = 30)
Intervention group
(n = 32)
Total
(N = 62)
Gender
 Female 18 (60%) 20 (62.5%) 38 (61%)
 Male 12 (40%) 12 (37.5%) 24 (39%)
Age (years)
 Median (range) 65 (34–81) 65 (18–81) 65 (18–81)
FEV1 (% predicted)
 Median (range) 75 (21–120) 67 (10–110) 68 (10–120)
BSI scorea
 Median (range) 6 (2–15) 7 (2–14) 6 (2–15)
BSI severity group
 Mild (score 0–4) 9 (30%) 13 (41%) 22 (35%)
 Moderate (score 5–8) 14 (47%) 13 (41%) 27 (44%)
 Severe (score > 8) 7 (23%) 6 (19%) 13 (21%)
Time since diagnosis (years)
 Median (range) 6 (0.5–70) 15 (0.25–70) 10 (0.25–70)
  > 10 9 (30%) 17 (53%) 26 (42%)
  > 5 ≤ 10 5 (17%) 2 (6%) 7 (11%)
  > 1 ≤ 5 10 (33%) 6 (19%) 16 (26%)
  > 6 months ≤ 1 year 5 (17%) 3 (9%) 8 (13%)
  ≤ 6 months 1 (3%) 3 (9%) 4 (6%)
Bronchiectasis aetiology
 Idiopathic
 Post-infection 12 (40%) 10 (31%) 22 (35%)
 Secondary to chronic asthma/COPD 6 (20%) 11 (34%) 17 (27%)
 Immune deficiency associated 7 (23%) 5 (16%) 12 (19%)
 Otherb 2 (7%)
3 (10%)
1 (3%)
5 (16%)
3 (5%)
8 (13%)
Exacerbations per year
  < 3 13 (43%) 10 (31%) 23 (37%)
  ≥ 3 17 (57%) 22 (69%) 39 (63%)
Use of home intravenous antibiotics
 Y 8 (27%) 15 (47%) 23 (37%)
 N 22 (73%) 17 (53%) 39 (63%)
Clinic attended
 Specialist 28 (93%) 30 (94%) 58 (94%)
 General 2 (7%) 2 (6%) 4 (6%)
Prior bronchiectasis hospital admissions
 Y 16 (53%) 25 (78%) 41 (66%)
 N 14 (47%) 7 (22%) 21 (34%)
Sputum microbiology
Pseudomonas aeruginosa 8 (27%) 9 (28%) 17 (27%)
 Otherc 8 (27%) 11 (34%) 19 (31%)
 Not colonised 13 (43%) 11 (34%) 24 (39%)
 No samples 1 (3%) 1 (3%) 2 (3%)
Drug treatments
 Azithromycin 10 (33%) 18 (56%) 28 (45%)
 Nebulised antibiotics 6 (20%) 3 (9%) 9 (15%)
Devices used to access Internet/resource
 Mobile 2 (7%) 8 (25%) 10 (16%)
 Tablet 13 (43%) 10 (31%) 23 (72%)
 PC/laptop 28 (93%) 28 (88%) 56 (90%)
 No access 0 1 (3%) 1 (2%)
Previous bronchiectasis information seeking
 None 9 (30%) 5 (16%) 14 (23%)
 Paper 9 (30%) 14 (44%) 23 (37%)
 Online 14 (47%) 16 (50%) 30 (48%)
 In person 4 (13%) 3 (9%) 7 (11%)
  1. Abbreviations: BSI Bronchiectasis Severity Index, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 s, PC personal computer
  2. aNewcastle Bronchiectasis Severity Index, computed tomographic scoring not included
  3. bPink disease, rheumatoid arthritis, Marfan syndrome, connective tissue disease, granulomatosis with polyangiitis
  4. cHaemophilus influenzae, Klebsiella spp., Staphylococcus aureus, Serratia marcescens, Moraxella catarrhalis, Escherichia coli